Previous 10 | Next 10 |
2024-03-29 10:45:03 ET Bristol-Myers Squibb Co. (BMY) BMY is trading UP for the last 5 days, and it at trading at $54.28 with volume of 9,234,665 and a one day change of $1.02 (1.92%). Bristol-Myers Squibb Co. has a 52-week low of 47.58 and a 52-week high of $71.07. The business's 5...
2024-03-28 16:59:39 ET Summary Bristol Myers Squibb's market capitalization has declined significantly due to the impending expiration of patents for its flagship drugs. Bristol Myers Squibb's high debt levels add to the financial strain, requiring strategic measures to survive an...
2024-03-28 16:39:29 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb Is Not A Buy For Me Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Pa...
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C -Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Bristol Myers Squib...
Bristol Myers Squibb (NYSE: BMY) today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to severe active Crohn’s diseas...
2024-03-28 10:45:02 ET Bristol-Myers Squibb Co. (BMY) BMY is trading UP for the last 5 days, and it at trading at $53.67 with volume of 1,446,339 and a one day change of $0.42 (0.78%). Bristol-Myers Squibb Co. has a 52-week low of 47.58 and a 52-week high of $71.07. The business's 5...
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial re...
2024-03-26 13:37:15 ET More on Nuvation Bio Nuvation Bio falls after AnHeart Therapeutics acquisition news Seeking Alpha’s Quant Rating on Nuvation Bio Historical earnings data for Nuvation Bio Financial information for Nuvation Bio Read the ...
Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United Kingdom Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserve...
2024-03-25 13:07:32 ET Summary M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot ...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...